Abstract
The smallest independently folded antibody fragments, the domains, are emerging as promising scaffolds for candidate therapeutics and diagnostics that bind specifically targets of interest. The discovery of such binders is based on several technologies including structure-based design and generation of libraries of mutants displayed on phage or yeast, next-generation sequencing for diversity analysis, panning and screening of the libraries, affinity maturation of selected binders, and their expression, purification, and characterization for specific binding, function, and aggregation propensity. In this review, we describe these technologies as applied for the generation of engineered antibody domains (eAds), especially those derived from the human immunoglobulin heavy chain variable region (VH) and the second domain of IgG1 heavy chain constant region (CH2) as potential candidate therapeutics and diagnostics, and discuss examples of eAds against HIV-1 and cancer-related proteins.
Keywords: Antibody domains, human, library, phage display, scaffold, stability, therapeutics, yeast display.
Current Drug Discovery Technologies
Title:Discovery of Novel Candidate Therapeutics and Diagnostics Based on Engineered Human Antibody Domains
Volume: 11 Issue: 1
Author(s): Weizao Chen, Rui Gong, Tianlei Ying, Ponraj Prabakaran, Zhongyu Zhu, Yang Feng and Dimiter S. Dimitrov
Affiliation:
Keywords: Antibody domains, human, library, phage display, scaffold, stability, therapeutics, yeast display.
Abstract: The smallest independently folded antibody fragments, the domains, are emerging as promising scaffolds for candidate therapeutics and diagnostics that bind specifically targets of interest. The discovery of such binders is based on several technologies including structure-based design and generation of libraries of mutants displayed on phage or yeast, next-generation sequencing for diversity analysis, panning and screening of the libraries, affinity maturation of selected binders, and their expression, purification, and characterization for specific binding, function, and aggregation propensity. In this review, we describe these technologies as applied for the generation of engineered antibody domains (eAds), especially those derived from the human immunoglobulin heavy chain variable region (VH) and the second domain of IgG1 heavy chain constant region (CH2) as potential candidate therapeutics and diagnostics, and discuss examples of eAds against HIV-1 and cancer-related proteins.
Export Options
About this article
Cite this article as:
Chen Weizao, Gong Rui, Ying Tianlei, Prabakaran Ponraj, Zhu Zhongyu, Feng Yang and Dimitrov S. Dimiter, Discovery of Novel Candidate Therapeutics and Diagnostics Based on Engineered Human Antibody Domains, Current Drug Discovery Technologies 2014; 11 (1) . https://dx.doi.org/10.2174/15701638113109990032
DOI https://dx.doi.org/10.2174/15701638113109990032 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery The Potential of Modulating Small RNA Activity In Vivo
Mini-Reviews in Medicinal Chemistry Theranostic Nanomedicine; A Next Generation Platform for Cancer Diagnosis and Therapy
Mini-Reviews in Medicinal Chemistry Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Current Signal Transduction Therapy Oncolytic Adenovirus: Preclinical and Clinical Studies in Patients with Human Malignant Gliomas
Current Gene Therapy Future of Protease Activity Assays
Current Pharmaceutical Design Targeting Tumour Metastasis: The Emerging Role of Nanotechnology
Current Medicinal Chemistry Targeting Different Signaling Pathways with Antisense Oligonucleotides Combination for Cancer Therapy
Current Pharmaceutical Design Alphaviruses and their Derived Vectors as Anti-Tumor Agents
Current Cancer Drug Targets Prostate Cancer with Variants in CYP17 and UGT2B17 Genes: A Meta-Analysis
Protein & Peptide Letters Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways
Current Cancer Drug Targets Non-Melanoma Skin Cancer – Overview
Current Cancer Therapy Reviews In Vitro Metabolism of Phenstatin: Potential Pharmacological Consequences
Drug Metabolism Letters Recent Development of Anticancer Therapeutics Targeting Akt
Recent Patents on Anti-Cancer Drug Discovery Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease
Current Topics in Medicinal Chemistry Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Short, but Highly Concentrated, Direct Inhalations of Essential Oil Molecules Improve Poor Sleep Quality: A Natural History Controlled, Withingroup, Self-administration Field Pilot Study
Current Psychopharmacology Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics Neuroimmune Interactions and Psychologycal Stress Induced by Cohabitation with a Sick Partner: A Review
Current Pharmaceutical Design Prostate Carcinogenesis: Insights in Relation to Epigenetics and Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets